Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Evaluation of the influence of particle size of aerosolized AMP on bronchial responsiveness in patients with asthma and the effects of treatment with ciclesonide versus fluticasone (protocol BY9010/NL101).

- candidate number2141
- NTR NumberNTR711
- Date ISRCTN created21-jul-2006
- date ISRCTN requested19-jul-2006
- Date Registered NTR22-jun-2006
- Secondary IDsN/A 
- Public TitleEvaluation of the influence of particle size of aerosolized AMP on bronchial responsiveness in patients with asthma and the effects of treatment with ciclesonide versus fluticasone (protocol BY9010/NL101).
- Scientific TitleEvaluation of the influence of particle size of aerosolized AMP on bronchial responsiveness in patients with asthma and the effects of treatment with ciclesonide versus fluticasone (protocol BY9010/NL101).
- ACRONYMBY9010/NL101 study
- hypothesisThe aim of this study is to investigate airway responsiveness to increasing doses of large particle and small particle aerosolized AMP and the changes in responsiveness to both challenges after treatment with ciclesonide in comparison with fluticasone.
- Healt Condition(s) or Problem(s) studiedAsthma
- Inclusion criteria1. Written informed consent; 2. Outpatients males or females; 3. Good health with the exception of asthma; 4. Age 18 up to and including 60 years; 5. History of bronchial asthma (according to GINA 2004); 6. FEV1 > 1.20L, measured at least 6 hours after the last use of rescue medication; 7. Atopy shown by positive skin prick test to common allergen (historic tests are accepted, if results are available and test was done within 3 years prior to visit B0); 8. Stable asthma (no exacerbation or relevant respiratory tract infection within 2 months prior to the study); 9. Patients who are steroid-naive or who have been pretreated with inhaled glucocorticosteroid of up to 500 g/d fluticasone or equivalent alone or in combination with long-acting beta-agonists at a constant dosage for at least 28 days prior to visit B0.
- Exclusion criteriaThe presence of any one of the following will cause exclusion of the patient: a. Diseases and health status: 1. Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation; 2. Concomitant severe diseases, diseases expected to interfere with the outcome of the study and diseases which are contra-indications for the use of inhaled steroids (e.g. active or inactive pulmonary tuberculosis or relevant fungal, bacterial or viral infections of the lower respiratory tract demanding specific treatment); 3. Suffering from COPD (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function; 4. Hospitalization because of asthma during the previous 6 months prior to visit B0; 5. One asthma exacerbation within 2 months or more than 3 exacerbations within the last year prior to visit B0; 6. Ex-smokers with > 10 pack years, or having smoked within 1 year prior to visit B0; 7. Current smokers; 8. Positive response to saline challenge at baseline visits B1, B2 or B3 (defined as 20% fall in FEV1); 9. PC20 > 160 mg/ml to AMP-ATS at B1; 10. FEV1 ≤ 1.20 l prior to each bronchial challenge test; b. Medications: 11. Use of systemic steroids within 4 weeks (injectable depot steroids 6 weeks) prior to visit B0 or more than 1 course during the last 6 months prior to visit B0; 12. Use of other drugs not allowed (see 7.4); 13. Washout times of drugs defined under 7.4 cannot be adhered to; 14. Known or suspected hypersensitivity to inhaled steroids or to the other excipients of the inhalatio devices; 15. Intolerance to salbutamol and excipients; 16. Beginning of immunotherapy during the patient's participation in the study or having begun an immunotherapy less than 3 months prior to visit B0 or alternation i regimen of an immunotherapy during the study period; c. Common criteria: 17. Pregnancy; 18. Intention to become pregnant during the course of the study; 19. Breast feeding; 20. Lack of safe contraception: Safe contraception is defined as follows: female patients of childbearing potential not using and not willing to continue using a medically reliable method of contraception for the entire study duration such as oral, injectable or implantable contraceptives or intrauterine contraceptive devices unless they are surgically sterilized/hysterectomized or post-menopausal > 1 year or who are not using any other method considered sufficiently reliable by the investigator in individual cases; 21. Participation in another study within the 30 days preceding and during the present study; 22. Previous enrollment into the current study; 23. Enrollment of the investigator, his/her family members, employeees and other dependent persons; 24. Known or suspected non-compliance, alcohol or drug abuse; 25. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders; 26. Reversal of sleep pattern (e.g. night shift workers).
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlActive
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-apr-2006
- planned closingdate1-jan-2008
- Target number of participants40
- InterventionsThe study is set up as a randomised, double-blind, dubbeldummy study in two parallel groups. In period 1 (5 weeks) all the patients get an inhaler with Ventolin which they can use during both study periods whenever they need to, but not for 6 hour priors to a visit. The patient will take 1 puff of 100 g fluticasone twice daily in the morning and evening. After five weeks (during the 4th visit in period 1) the investigator will select the patients that fulfill the inclusion criteria for period 2. Period 2 (5 weeks) begins during the last visit of period 1. Patients will randomly be assigned to one of two treatment groups: group 1 receives ciclesonide 160 g in the morning, and a placebo twice daily, group 2 receives fluticasone 100 g twice daily and a placebo in the morning. Then all the patients receive 4 inhalers (2 DPIs (dry powder inhalers) and 2 dose aerosols) for a period of 5 weeks. The patient takes 1 puff from DPI No. I twice daily and 1 puff from dose aerosol No. I in the morning. After thirty days, DPI No. 1 will be empty and the patient replaces both inhalers with the unused DPI inhaler No. II and dose aerosol No. II.
- Primary outcomeTo evaluate the effects of particle size of aerosolized AMP on the bronchial responsiveness in asthma.
- Secondary outcomeTo evaluate the effects of ciclesonide vs. fluticasone on large and small particile PC20 AMP.
- Timepoints
- Trial web siteN/A
- statusopen: patient inclusion
- Sponsor/Initiator Altana Pharma B.V.
- Funding
(Source(s) of Monetary or Material Support)
ALTANA Pharma B.V.
- PublicationsCohen J et al. (2005): Relationship between airway responsiveness to eurokinin A and methacholine in asthma. Pulm Pharmacol Ther 2005; 18(3): 171-6. Epub 2005 Jan 22. Crimi N et al. (2003): Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin A-induced bronchoconstriction. J Allergy Clin Immunol. 2003 Apr; 111(4): 833-9. O'Connor BJ et al. (2002a): Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial, ATS 2002 O'Connor BJ et al. (2002b): Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks, ERS 2002. Drollmann A et al. (2002): Ciclesonide shows high lung function deposition in 2D and 3D imaging, ATS 2002
- Brief summaryThe study consists of a 5-week baseline period and a 5-week treatment period. At B0 inhaled glucocorticosteroid and long-acting beta-agonists will be withdrawn, if applicable, and will be replaced with a 5-week baseline treatment with fluticasone 100 g b.i.d. and salbutamol as needed only. Steroid naive patients will also receive baseline treatment with fluticaseone 100 g b.i.d. Patients showing bronchial hyperresponsiveness to AMP-ATS at B1 (PC20 ≤ 160 mg/ml) after 4 weeks treatment with fluticasone will be eligible to continue with this study. After the 5-week baseline period patients will be randomized to receive either 160 g ciclesonide (ex-actuator) once daily in the morning or continue fluticasone 100 g twice daily for 5 weeks. The entire treatment period will be conducted in a double-blind, double-dummy, randomized, parallel-group design.
- Main changes (audit trail)
- RECORD22-jun-2006 - 24-jul-2006

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar